07:00 , Oct 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Transient receptor potential vanilloid 1 (TRPV1; VR1) In vitro and mouse studies suggest antagonizing TRPV1 could decrease inflammation in colitis and inflammatory bowel disease...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Alize Pharma, Bertin Technologies S.A.S., Ricerca, French National Institute of Health and Medical Research (Inserm), Lyon School of Veterinary Medicine cardiov

Alize launched the €3.9 million ($5.1 million) PREMAG collaborative research program to develop Alize's AZP-531.The group will develop the unacylated ghrelin analog for indications including cardiovascular complications of diabetes, cardioprotection following ischemia-reperfusion and cachexia associated...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Company News

Aterovax, Bertin Technologies S.A.S. sales and marketing update

Bertin's Spi-BIO subsidiary will exclusively distribute Aterovax's sPLA2 test for research use in Europe for three years. The test for secretory phospholipase A2 ( PLA2G2A ; sPLA2) activity in blood plasma is in pivotal testing...
07:00 , Sep 4, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Heat shock protein 70 (Hsp70) Studies in cell culture suggest that compounds that increase reactive oxygen species (ROS) may...